Compare SIBN & ODTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SIBN | ODTX |
|---|---|---|
| Founded | 2008 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 2018 | 2025 |
| Metric | SIBN | ODTX |
|---|---|---|
| Price | $23.05 | $19.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 8 |
| Target Price | $26.78 | ★ $34.67 |
| AVG Volume (30 Days) | ★ 876.7K | 285.5K |
| Earning Date | 11-02-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.33 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $67,301,000.00 | N/A |
| Revenue This Year | $15.53 | N/A |
| Revenue Next Year | $15.50 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 21.53 | N/A |
| 52 Week Low | $11.48 | $15.10 |
| 52 Week High | $25.92 | $29.05 |
| Indicator | SIBN | ODTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.59 | 47.95 |
| Support Level | $18.51 | $18.87 |
| Resistance Level | $25.92 | $19.60 |
| Average True Range (ATR) | 1.47 | 1.69 |
| MACD | -0.21 | 0.03 |
| Stochastic Oscillator | 55.62 | 30.57 |
SI-BONE Inc is a medical device company that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ, and iFuse Bedrock Granite, which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.